Conference on HIV Vaccines

艾滋病毒疫苗会议

• 批准号: 6887271
• 负责人: Kent J. Weinhold
• 金额: $ 3.5万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-02-01 至 2006-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6887271
• 关键词: AIDS; AIDS vaccines; human immunodeficiency virus; meeting /conference /symposium; travel

DESCRIPTION (provided by applicant): The need to develop a vaccine for AIDS has never been so urgent. Progress toward the development and testing of an efficacious HIV-1 vaccine continues at an accelerated pace with a broad array of new basic science concepts and strategies under evaluation at the pre-clinical level as well as a significant expansion in the Phase l/ll clinical testing of promising vaccine candidates. The next two years represents a period in vaccine development in which the 'pipeline' of candidate vaccines making the transition from pre-clinical to clinical testing is extremely rich. It is estimated that nearly 20 new Phase l/ll clinical vaccine trials will be enrolling participants during 2004 alone. At the same time, there is a need to foster the development of new vaccine strategies based on hypothesis-driven research in the laboratories of the world's leading scientists. Considerable efforts are underway to better understand both the genetic diversity and antigenic composition of the virus as well as the immune responses that may be capable of containing the virus and the complex mechanisms used by the virus to evade these responses. Rapid dissemination of new information from basic to applied science must continue on a bi-directional basis if progress toward an efficacious vaccine is to be sustained. It is essential that both bench scientists and clinicians form a solid partnership in this venture. The key to establishing and preserving such crucial alliances is a regular scientific forum that encourages an open and objective exchange of ideas and new information. In planning this meeting, we sought to cover a wide range of topics that span all aspects of HIV development and testing from basic science insights through Phase l/ll clinical vaccine testing. Particular emphasis will be placed on current scientific challenges to successful vaccine development as well as future prospects to meet these challenges. An important aspect of the meeting is the opportunity for graduate students and postdoctoral fellows to present their original data in a highly interactive, relaxed environment that stimulates open discussion with established, knowledgeable scientific leaders in the field.

描述（由申请人提供）：开发艾滋病疫苗的需求从未如此迫切。有效的 HIV-1 疫苗的开发和测试进展继续加快，在临床前水平上评估了一系列新的基础科学概念和策略，并在 l/ll 期临床中显着扩展测试有前途的候选疫苗。未来两年是疫苗开发的一个时期，从临床前测试过渡到临床测试的候选疫苗“管道”非常丰富。据估计，仅 2004 年就有近 20 个新的 I/II 期临床疫苗试验将招募参与者。与此同时，需要在世界领先科学家实验室的假设驱动研究的基础上促进新疫苗策略的开发。人们正在进行大量努力，以更好地了解病毒的遗传多样性和抗原组成，以及可能能够遏制病毒的免疫反应，以及病毒用来逃避这些反应的复杂机制。如果要保持有效疫苗的进展，就必须继续在双向基础上快速传播从基础科学到应用科学的新信息。基础科学家和临床医生在这项事业中建立牢固的合作伙伴关系至关重要。建立和维持这种重要联盟的关键是定期举办科学论坛，鼓励开放、客观的思想和新信息交流。在计划这次会议时，我们力求涵盖广泛的主题，涵盖艾滋病毒开发和测试的各个方面，从基础科学见解到第一/第二阶段临床疫苗测试。将特别强调当前成功开发疫苗所面临的科学挑战以及应对这些挑战的未来前景。会议的一个重要方面是让研究生和博士后有机会在高度互动、轻松的环境中展示他们的原始数据，从而激发与该领域知名、知识渊博的科学领导者的公开讨论。